KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Share-based Compensation: 2013-2025

Historic Share-based Compensation for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $13.7 million.

  • Xenon Pharmaceuticals' Share-based Compensation rose 5.41% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year increase of 14.88%. This contributed to the annual value of $50.7 million for FY2024, which is 56.67% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Share-based Compensation stood at $13.7 million, which was down 0.06% from $13.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Share-based Compensation ranged from a high of $14.7 million in Q2 2024 and a low of $2.0 million during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $12.2 million (2025), whereas its average is $11.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 117.25% in 2022, then dropped by 6.82% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Share-based Compensation (Quarterly) stood at $2.7 million in 2021, then skyrocketed by 114.86% to $5.8 million in 2022, then skyrocketed by 57.98% to $9.2 million in 2023, then surged by 48.10% to $13.6 million in 2024, then increased by 5.41% to $13.7 million in 2025.
  • Its Share-based Compensation was $13.7 million in Q3 2025, compared to $13.7 million in Q2 2025 and $12.2 million in Q1 2025.